


* Not considered, due to in French.



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/1-01

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

4

Complete if Known

Application Number	10/523184
Filing Date	28-Jan-2005
First Named Inventor	Mertens
Art Unit	1626
Examiner Name	YONGB CHU
Attorney Docket Number	1592 WO/US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
yz		DEEHAN, B et.al. "Uptake and Distribution of L-3-I-125 Lodo-alpha-methyl tyrosine in exp. rat..." Euro.J.of Nuc. Med., Feb.,1993, pg. 101-106,Vol. 20, no. 2, Berlin, DE	
		WESTER H.J. et.al. "Synth. and Radi. of O-(¹⁸ F)fluorethyl)-L-tyrosine for tum. imag.", J. of Nuc. Med.: Off. Publ., Soc. of Nuc.Med.,Jan,1999,pp.205-212,Vol. 40,no.1	
		ISHIWATA K. et.al.:"Synth. and Rad. Dos. of 4-Borono-2-(¹⁸ F)Fluoro...", Intl. Jnl. of Rad., June 25, 1990, pp. 325-328, vol. 42, no. 2, Pergamon PressLTD, GB	
		KAWAI K et. al."Monoiodo-D-Tyrosine, an artif. Amino Acid...", Nuc. Med. and Bio., 1990, pp. 369-376, vol. 17, no. 4, Pergamon, Oxford, GB	
		BERGSTROM, et.al."PET study of methionine accum. in glioma...", Jnl of Comp. Assist. Tomography, 1987,pp.208-213,Vol. 11, no. 2,Raven Press, NY	
		COENEN, et.al."Cerebral metabolism of L-2- ¹⁸ F-...", J. Nucl. Med., Aug, 1989, pp.1367-1372, Vol.30,no.8	
		BIERSACK, et. al."Imaging of brain tumors with L-3-[¹²³ I]-iodo...", J. Nucl. Med., 1989, pp.110-112, Vol.30	
		JAGER, P.L.et.al.,"Uptake mechanism of L-3-[¹²⁵ I]iodo-alpha-methyl-..."Nuc. Med. Comm., 2001,pp.87-96,Vol.22, no.1, Lippincott Williams & Wilkins	
		LAHOUTTE, et.al."In vitro charac. of the influx of 3-[¹²⁵ I]iodo-...", Nuc. Med. of Bio., 2001,pp.129-134, Vol. 28,Elsevier Science Inc.	
yz		HEISS, et.al."Invest. of transport mech. and uptake kinetics of O-2-[¹⁸ f]fluoroethyl)-L-...", J. Nuc. Med., 1999,pp. 1367-1373, Vol. 40	

Examiner
Signature

Yong C


Date
Considered

2-28-2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

3

of

4

Complete if Known

Application Number	10/523184
Filing Date	28-Jan-2005
First Named Inventor	Mertens
Art Unit	1626
Examiner Name	YONG CHU
Attorney Docket Number	1592 WO/US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
yz		VEKEMAN, et.al., "L-[2-radioiodo]Tyrosine, a new potential protein synthesis...", Eur. J. Nuc. Med., 1999, pp.971, Vol.26, no.9,	
		MERTENS, et.al. "Uptake study of L-2-I251-o-Tyrosine, ..." Eur. J. Nuc. Med., 2000, p.1063, Vol. 27	
		MERTENS, et.al. "New approach of cell uptake kinetics of L-2-123I-Tyr...", Eur. J. Nuc. Med. Mol. Imag., 2002, p.S377-P722, Vol. 29	
		SAMNICK, et.al. "Initial evaluation on the feasibility of SPECT with p-iodo-L-phenylalanine...", Nuc. Med. Com., 2002, pp. 121-130, Vol. 23, no.2, Lippincott Williams & Wilkins	
		RAU, et.al. "O-(2-[(18)F]Fluoroethyl)-L-tyrosine (FET): a tracer for differentiation...", Eur. J. Nuc. Med. Mol. Imag., 2002, pp.1039-1046, Vol. 29, no.8, Springer-Verlag	
yz		WESTER, et.al. "Synthesis and Radiopharm. of O-(2-[18F]fluoroethyl)-L...", J. Nucl. Med., 1999, pp. 205-212, Vol. 40	cited
		MERTENS, et.al. "Synthesis, radiosynthesis and in vitro charac...", Nuc. Med. Bio., 2004, pp.739-746, Vol. 31, Elsevier Inc.	
		MERTENS, et.al. "L-[2-Radioiodo]-Tyrosine a potential tumour tracer for SPECT...", J. of Label. Comp. and Radiopharm., May, 2001, pp.S860-S862, Vol.44(Suppl. 1)	
		HAMACHER, et.al. "Efficient routine production of the 18F-labelled...", Applied Rad. and Isotopes, 2002, pp.853-856, Vol.40(issue 6), Elsevier Science, Ltd.	
yz		HAMACHER, et.al. "Convenient synth. of n.c.a. O-(2-[18F]Fluoroethyl)-...", J. Labelled Cpd. Radiopharm., 2001, p.S855, Vol. 44	


Examiner
Signature*Yong Chu*Date
Considered

2-28-2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4

of

4

Application Number

10/523184

Filing Date

28-Jan-2005

First Named Inventor

Mertens

Art Unit

1626

Examiner Name

YONG CHU

Attorney Docket Number

1592 WO/US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
yz		LAHOUTTE, et.al."Comparative Biodistrib. of Iodinated Amino Acids in Rats:...", Biodistrib. of Iodinated Aminos Acids, 2003, pp.1489-1494, Vol.44, no. 9	

Examiner
Signature

Yong Chu

Date
Considered

2-28-2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.